trending Market Intelligence /marketintelligence/en/news-insights/trending/RBeyra4TZ-UJmggPoHh3Tg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Recro Pharma handed 2nd US FDA rejection for non-opioid painkiller

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Recro Pharma handed 2nd US FDA rejection for non-opioid painkiller

The U.S. Food and Drug Administration rejected for the second time Recro Pharma Inc.'s application for approval of its intravenous meloxicam for the management of moderate to severe pain.

The reason for the latest complete response letter from the regulatory agency was the delayed onset of the non-opioid drug, which did not meet expectations for intravenous treatments.

In addition, the FDA expressed concerns about the drug's ability to meet patient and prescriber needs as a single therapy for acute pain.

The Malvern, Penn.-based company had resubmitted its application in September 2018 following a previous complete response letter from the FDA in May that year citing similar concerns.

"We are dedicated to bringing this and other non-opioid pain products to the market to help address the crippling opioid epidemic our country currently faces," Recro President and CEO Gerri Henwood said in a March 22 press release.

Recro said it strongly disagrees with the FDA's interpretation and its views on the clinical utility of the drug in the acute pain setting. It plans to request a meeting with the regulator to continue the regulatory process.